• -

TENS PEMF therapy in the management of Autism Spectrum Disorder

The following studies represent the clinical evidence for the use of TENS PEMF therapy in the management of Autism Spectrum Disorder. Please note these studies were not done on the Rife PEMF device, but do represent outputs available on our devices.

PEMF for Boosting the Immune System

rTMS neuromodulation improves electrocortical functional measures of information processing and behavioral responses in autism Post-TMS evaluations showed decreased irritability and hyperactivity on the Aberrant Behavior Checklist (ABC), and decreased stereotypic behaviors on the Repetitive

Behavior Scale (RBS-R). Results from our study indicate that rTMS improves executive functioning in ASD as evidenced by normalization of ERP responses and behavioral reactions (RT,

accuracy) during executive function test, and also by improvements in clinical evaluations.

18 sessions of 1 Hz rTMS applied over the dorso-lateral prefrontal cortex
A double-blind, randomized trial of deep repetitive transcranial magnetic stimulation (rTMS) for autism spectrum disorder. Participants in the active condition showed a near significant reduction in self-reported social relating symptoms from pre-treatment to one-month follow-up, and a significant reduction in social relating symptoms (relative to sham participants) for both post-treatment assessments. Those in the active condition also showed a reduction in self-oriented anxiety during difficult and emotional social situations from pre-treatment to one-month follow-up. There were no changes for those in the sham condition. 5 Hz, 10-s train duration, 20-s inter-train interval) for 15 min (1500 pulses per session)
Effect of Anodal Transcranial Direct Current Stimulation on

Autism: A Randomized Double-Blind Crossover Trial

The CARS revealed a statistically significant amelioration of total score (𝑃 <0.001; Table 2). After 7 days of anodal tDCS, the tDCS group shifted from 34.95 to32.2. There was statistical change in total ATEC score observed in the active compared to sham group

(𝐹(1,39) = 23.143; 𝑃 < 0.001), as well as in health and

behavioral problem (𝐹(1,39) = 4.815; 𝑃 = 0.034), sociability

(𝐹(1,39) = 6.525; 𝑃 = 0.015), and sensory/cognitive awareness

(𝐹(1,39) = 6.171; 𝑃 = 0.018). The between group

CGAS showed statistical increase in the active compared

to sham group at 7 days after treatment (𝑃 = 0.042).

Eighteen of 20 children (90%) in the active tDCS group

demonstrated an increase in the score (from mean score

54.35 ± 11.07 at baseline to 60.00 ± 10.57 at the end of

treatment), whereas 1 of 20 children (5%) in the sham group

showed an improvement. Among those who received active tDCS, only 2 children were reported to be “minimally worse,” whereas the rest were rated as “much improved” (9 of 20) and “minimally improved” (8 of 20). This gave a response rate of 85% for active tDCS. In the sham group, 3 children were rated as

“much improved” to some extent, whereas 4 children were

reported to have “minimally improved.” Interestingly, 7 children in the sham group were rated as “worsened” after

treatment. Although the mechanisms of action of tDCS and rTMS

are not fully understood, both techniques appear to produce

similar changes in the activity of neuronal cell and thus

may lead to similar clinical outcomes

5 consecutive days of 1mA anodal or sham tDCS stimulation

(depending on order assignment) for 20 min;

Transcranial direct current stimulation for hyperactivity and noncompliance in autistic disorder. Eight out of 10 study completers improved in their abnormal behaviors, reaching an average reduction of 26.7% of the total ABC score. The remaining two patients showed no changes. In the whole group of completers, among the five subscales contributing to the significant reduction of the total score, the most remarkable and statistically significant change was seen in the subscale assessing hyperactivity and non-compliance (-35.9%, P = 0.002). No adverse effects were reported. Inhibitory tDCS improved the ABC rating scores for autistic behaviors. Owing to its ease of use, cost-effectiveness and the limited availability of specific treatment strategies, tDCS might be a valid therapeutic option to be tested in autistic patients. 10 daily applications of 20 min/1.5 mA/cathodal (inhibitory) tDCS over the left dorso-lateral pre-frontal cortex
Transcranial Direct Current Stimulation for Autistic Disorder Mr P manifested an overall substantial improvement in his abnormal behaviors, as evidenced by a 40.2% reduction in the total ABC score compared with the basal score. A direct

current of 1.5 mA was applied for 20 minutes every day.

To keep up to date on the latest studies, and clinical evidence for TENS PEMF therapy in the management of Autism Spectrum Disorder, please feel free to join our newsletter, or check back periodically.